119 related articles for article (PubMed ID: 7586948)
21. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis.
Arns PA; Adedoyin A; DiBisceglie AM; Waggoner JG; Hoofnagle JH; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1997 Nov; 62(5):527-37. PubMed ID: 9390109
[TBL] [Abstract][Full Text] [Related]
22. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
23. Phenotyping polymorphic drug metabolism in the French Caucasian population.
Jacqz E; Dulac H; Mathieu H
Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
[TBL] [Abstract][Full Text] [Related]
25. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
Saner H; Gurtner HP; Preisig R; Küpfer A
Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
[TBL] [Abstract][Full Text] [Related]
26. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
[TBL] [Abstract][Full Text] [Related]
27. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
28. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
Küpfer A; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
[TBL] [Abstract][Full Text] [Related]
30. Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry.
Jansson B; Elsherbiny D; Simonsson US
Rapid Commun Mass Spectrom; 2006; 20(3):463-72. PubMed ID: 16395737
[TBL] [Abstract][Full Text] [Related]
31. Lack of pharmacokinetic interaction between dextromethorphan, coumarin and mephenytoin in man after simultaneous administration.
Endres HG; Henschel L; Merkel U; Hippius M; Hoffmann A
Pharmazie; 1996 Jan; 51(1):46-51. PubMed ID: 8999435
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man.
Wedlund PJ; Sweetman BJ; Wilkinson GR; Branch RA
Drug Metab Dispos; 1987; 15(2):277-9. PubMed ID: 2882992
[No Abstract] [Full Text] [Related]
33. Polymorphic drug metabolism.
Relling MV
Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
[TBL] [Abstract][Full Text] [Related]
34. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
35. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
Jurima M; Inaba T; Kadar D; Kalow W
Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
[TBL] [Abstract][Full Text] [Related]
37. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.
Reviriego J; Bertilsson L; Carrillo JA; Llerena A; Valdivielso MJ; Benítez J
Eur J Clin Pharmacol; 1993; 44(6):593-5. PubMed ID: 8405020
[TBL] [Abstract][Full Text] [Related]
38. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
[TBL] [Abstract][Full Text] [Related]
39. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects.
Zhang YA; Reviriego J; Lou YQ; Sjöqvist F; Bertilsson L
Clin Pharmacol Ther; 1990 Nov; 48(5):496-502. PubMed ID: 2225709
[TBL] [Abstract][Full Text] [Related]
40. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
